These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 24359239)

  • 1. Drug-drug interaction between bosutinib and warfarin.
    Chintakuntlawar AV; Finnes HD; Tefferi A; Pardanani A
    Leuk Lymphoma; 2014 Sep; 55(9):2213-4. PubMed ID: 24359239
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
    Daud AI; Krishnamurthi SS; Saleh MN; Gitlitz BJ; Borad MJ; Gold PJ; Chiorean EG; Springett GM; Abbas R; Agarwal S; Bardy-Bouxin N; Hsyu PH; Leip E; Turnbull K; Zacharchuk C; Messersmith WA
    Clin Cancer Res; 2012 Feb; 18(4):1092-100. PubMed ID: 22179664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bosutinib treatment for Philadelphia chromosome-positive leukemias.
    Bethelmie-Bryan B; Lord K; Holloway S; Khoury HJ
    Future Oncol; 2014 Feb; 10(2):179-85. PubMed ID: 24490604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extramedullary blast crisis in a chronic myeloid leukaemia patient after achieving a major molecular response with bosutinib.
    Nakajima R; Matsuo T; Sumiyoshi R; Saito S; Yamamoto T; Matsumoto K; Akiyama N; Ooi J; Ota Y; Shirafuji N; Tashiro H
    Br J Haematol; 2022 Jan; 196(1):e9-e11. PubMed ID: 34378212
    [No Abstract]   [Full Text] [Related]  

  • 5. Bosutinib more effective than imatinib in CML.
    Gourd E
    Lancet Oncol; 2017 Dec; 18(12):e716. PubMed ID: 29129440
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.
    Cortes JE; Gambacorti-Passerini C; Kim DW; Kantarjian HM; Lipton JH; Lahoti A; Talpaz M; Matczak E; Barry E; Leip E; Brümmendorf TH; Khoury HJ
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):684-695.e6. PubMed ID: 28807791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
    Stansfield L; Hughes TE; Walsh-Chocolaad TL
    Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib.
    Redaelli S; Perini P; Ceccon M; Piazza R; Rigolio R; Mauri M; Boschelli F; Giannoudis A; Gambacorti-Passerini C
    J Hematol Oncol; 2015 Jul; 8():81. PubMed ID: 26149173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New kinase inhibitor approved for CML.
    Traynor K
    Am J Health Syst Pharm; 2012 Nov; 69(21):1846. PubMed ID: 23111662
    [No Abstract]   [Full Text] [Related]  

  • 10. Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
    Hill BG; Kota VK; Khoury HJ
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):765-70. PubMed ID: 24875651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bosutinib for the treatment of chronic myeloid leukemia.
    Doan V; Wang A; Prescott H
    Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Syed YY; McCormack PL; Plosker GL
    BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.
    Hsyu PH; Mould DR; Upton RN; Amantea M
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):209-18. PubMed ID: 23070145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
    Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
    Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bosutinib: a novel second-generation tyrosine kinase inhibitor.
    Isfort S; Keller-v Amsberg G; Schafhausen P; Koschmieder S; Brümmendorf TH
    Recent Results Cancer Res; 2014; 201():81-97. PubMed ID: 24756786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
    Keller G; Schafhausen P; Brummendorf TH
    Expert Rev Hematol; 2009 Oct; 2(5):489-97. PubMed ID: 21083014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New treatment option for patient with CML-bosutinib].
    Takahashi N
    Gan To Kagaku Ryoho; 2015 May; 42(5):563-7. PubMed ID: 26054091
    [No Abstract]   [Full Text] [Related]  

  • 18. Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
    Rusconi F; Piazza R; Vagge E; Gambacorti-Passerini C
    Expert Opin Pharmacother; 2014 Apr; 15(5):701-10. PubMed ID: 24479382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of Bosutinib for the treatment of chronic myeloid leukemia.
    Kong JH; Khoury HJ; Kim AS; Hill BG; Kota V
    Expert Opin Drug Saf; 2017 Oct; 16(10):1203-1209. PubMed ID: 28774214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bosutinib.
    Keller G; Schafhausen P; Brümmendorf TH
    Recent Results Cancer Res; 2010; 184():119-27. PubMed ID: 20072835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.